Metagenomi Therapeutics, Inc. (MGX)
Data as of , from SEC Form 4 filings.
See up to 3 months of MGX. The 7-day demo opens the 1M and 3M ranges and puts MGX on your watchlist.
Start 7-day demoLatest MGX insider trades
About Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
- EMERYVILLE, CA
- 113
- 2024
- XNAS
MGX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 20,000 | $23K |
| Open-market sale | 3 | 4,409 | $5K |
MGX insider transactions (Form 4)
3828 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Laurence Reid - Director | Open-market purchase | Common Stock | 19,883 | $1.17 footnote F1 | $23K | |
| Laurence Reid - Director | Open-market purchase | Common Stock | 117 | $1.18 | $138 | |
| ||||||
| Matthew Wein - Officer | Open-market sale | Common Stock | 358 | $1.16 | $415 | |
| Jian Irish - Officer | Open-market sale | Common Stock | 2,140 | $1.16 | $2K | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,911 | $1.16 | $2K | |
| Laurence Reid | Grant or award | Stock Option (Right to Buy) | 17,400 | $0.00 | - | |
| Willard H. Dere | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
 Eric Bjerkholt | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
| Juergen Eckhardt | Grant or award | Stock Option (Right to Buy) | 21,000 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 2,884 | $1.30 | $4K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 3,737 | $1.30 | $5K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 558 | $1.30 | $725 | |
| Jian Irish - Officer | Grant or award | Common Stock | 46,000 footnote F1 | $0.00 | - | |
| Jian Irish - Officer | Grant or award | Stock Option (Right to Buy) | 276,000 | $0.00 | - | |
| ||||||
| Matthew Wein - Officer | Grant or award | Common Stock | 11,000 footnote F1 | $0.00 | - | |
| Matthew Wein - Officer | Grant or award | Stock Option (Right to Buy) | 68,000 | $0.00 | - | |
| ||||||
| Pamela Wapnick - Officer | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| Pamela Wapnick - Officer | Grant or award | Stock Option (Right to Buy) | 144,000 | $0.00 | - | |
| ||||||
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,581 | $1.60 | $3K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 482 | $1.60 | $771 | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,607 | $1.60 | $3K | |
| Jian Irish - Officer | Gift | Common Stock | 228,462 | $0.00 | - | |
| Brian C. Thomas | Open-market sale | Common Stock | 3,830 | $1.77 | $7K | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 199 | $1.77 | $353 | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,576 | $1.77 | $3K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,602 | $1.77 | $3K | |
| Brian C. Thomas | Open-market sale | Common Stock | 2,701 | $1.81 | $5K | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,576 | $1.81 | $3K | |
| Pamela Wapnick - Officer | Grant or award | Common Stock | 120,000 | $1.60 | $192K | |
| Jian Irish - Officer | Open-market sale | Common Stock | 1,602 | $1.81 | $3K | |
| Jian Irish - Officer | Grant or award | Common Stock | 37,500 | $1.60 | $60K | |
| Jian Irish - Officer | Grant or award | Common Stock | 211,000 | $1.60 | $338K | |
| Jian Irish - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| Matthew Wein - Officer | Open-market sale | Common Stock | 199 | $1.81 | $360 | |
| Matthew Wein - Officer | Grant or award | Common Stock | 96,000 | $1.60 | $154K | |
| Laurence Reid | Grant or award | Stock Option (Right to Buy) | 42,000 | $0.00 | - | |
| Eric Bjerkholt | Grant or award | Stock Option (Right to Buy) | 8,572 | $0.00 | - | |
| Pamela Wapnick - Officer | Open-market sale | Common Stock | 1,559 | $1.86 | $3K | |
MGX insider trading FAQ
What is the latest insider trade for MGX?
Metagenomi Therapeutics, Inc. (MGX) had 4 insider filings in the last 90 days, with the most recent on 2026-09-11. The full record for MGX runs to 28 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying MGX stock?
2 insider purchases of MGX were filed in the last 90 days, totaling $23K.
How many insiders are selling MGX stock?
3 insider sales of MGX were filed in the last 90 days, totaling $5K.
Where can I see MGX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects MGX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Laurence Reid view on EDGAR
- - Matthew Wein view on EDGAR
- - Jian Irish view on EDGAR
- - Pamela Wapnick view on EDGAR
- - Laurence Reid view on EDGAR
- - Willard H. Dere view on EDGAR
- - Eric Bjerkholt view on EDGAR
- - Juergen Eckhardt view on EDGAR
- - Pamela Wapnick view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where MGX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow MGX with a 7-day demo
- MGX on your watchlist
- Every MGX Form 4 filing on record
- Up to 3 months of MGX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
